It will only be a bloodbath if people give up their shares. I own a boatload and will not be selling one. The quarter was disappointing, but annual revenue projections of $55-57 MM. Not shabby. And you don't think that Stuart Tomc is working on multiple fronts for new distribution? And people have been asking for a senior marketing person, and it looks like they just hired one. Ask yourself how you compete with a store front who is receiving free product?
Do you get the sense that Duffy MacKay is doing a lot of out front and behind the scenes work with FDA? Oh yeah, and he knows them well, having been a leader in that space for 10 plus years with CRN.
For the first time we got a lot more clarity about the drug program. Starting clinical trials in the first half of 2020. That is huge. The regulatory environment is a bit more friendly in Europe, I can tell you that from my experience in pharma.
I would guess that Tomc and company might be looking for international opportunities to sell product.
So big picture, down 7% in intense competition. We're still the market leader. We have a plan. Multiple divisions. Expanded capability. New leaders. Our day will come.
Don't help by giving away your shares.
MT